FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2246249321> ?p ?o ?g. }

• W2246249321 endingPage "2584" @default.
• W2246249321 startingPage "2584" @default.
• W2246249321 abstract "2584 Background: CV9201 is a therapeutic cancer vaccine for non small cell lung cancer (NSCLC) based on a novel vaccination technology using self-adjuvanted mRNA molecules. It comprises five mRNAs encoding NSCLC associated tumor antigens (NY-ESO1, Mage-C1, Mage-C2, Survivin, 5T4). Here, we report interim results of a phase I/IIa trial with CV9201 in stage IIIb/IV NSCLC patients that responded or stabilized after first line (chemo-) radiotherapy. Primary endpoint was assessment of safety and tolerability of CV9201 and secondary endpoints were evaluation of induction of immune response and assessment of anti-tumor activity. Methods: Patients were vaccinated intra-dermally up to five times in max. 15 weeks. Blood samples were taken before the first vaccination and two weeks after the 3rd and 5th vaccination. 3 patients were vaccinated in the phase I part of the study at each of three different dose levels (400µg, 800µg and 1600µg total mRNA administered). Enrollment was then expanded at the highest dose level within the phase IIa part. Peripheral blood mononuclear cells were analyzed for induction of effector and memory T cell subsets, B cells and CD4+CD25++ T regulatory cells during the course of vaccination. Antigen-specific B and T-cell responses against all antigens were analyzed by IgM and IgG ELISA, IFN-g ELISPOT, ICS and tetramer analysis. Results: Phase I safety analysis showed mainly treatment related grade 1 injection site reactions and grade 2 fever. Neither dose-limiting toxicity nor vaccine-related serious adverse events were reported. B-cell frequency increased and a significant (P< 0.004) shift from IgD+CD38+/- naïve B-cells towards IgD+CD38++ germinal center founder B-cells by > 2 fold was detected in 50% of 16 intermediate analyzed patients after 3 vaccinations. T-cell population shifted from effector to memory subtype 2 weeks after the final vaccination. Antigen-specific B cell, CD4+ and CD8+ T cell responses were detected during and after vaccination with CV9201. Conclusions: The interim analysis indicated that vaccination with CV9201 was safe and well tolerated by the study participants. Moreover, CV9201 led to an adaptive immune activation, and detectable antigen-specific humoral and cellular immune responses." @default.
• W2246249321 created "2016-06-24" @default.
• W2246249321 creator A5001797354 @default.
• W2246249321 creator A5005474411 @default.
• W2246249321 creator A5010938604 @default.
• W2246249321 creator A5012380788 @default.
• W2246249321 creator A5013658911 @default.
• W2246249321 creator A5027037303 @default.
• W2246249321 creator A5040708686 @default.
• W2246249321 creator A5042700545 @default.
• W2246249321 creator A5043050636 @default.
• W2246249321 creator A5043093544 @default.
• W2246249321 creator A5048499083 @default.
• W2246249321 creator A5051567097 @default.
• W2246249321 creator A5056592494 @default.
• W2246249321 creator A5065804797 @default.
• W2246249321 creator A5068350308 @default.
• W2246249321 creator A5070471459 @default.
• W2246249321 creator A5070900971 @default.
• W2246249321 creator A5072977147 @default.
• W2246249321 creator A5090261662 @default.
• W2246249321 date "2011-05-20" @default.
• W2246249321 modified "2023-09-25" @default.
• W2246249321 title "Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial." @default.
• W2246249321 doi "https://doi.org/10.1200/jco.2011.29.15_suppl.2584" @default.
• W2246249321 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28022259" @default.
• W2246249321 hasPublicationYear "2011" @default.
• W2246249321 type Work @default.
• W2246249321 sameAs 2246249321 @default.
• W2246249321 citedByCount "19" @default.
• W2246249321 countsByYear W22462493212012 @default.
• W2246249321 countsByYear W22462493212013 @default.
• W2246249321 countsByYear W22462493212014 @default.
• W2246249321 countsByYear W22462493212016 @default.
• W2246249321 countsByYear W22462493212017 @default.
• W2246249321 countsByYear W22462493212018 @default.
• W2246249321 countsByYear W22462493212019 @default.
• W2246249321 countsByYear W22462493212020 @default.
• W2246249321 countsByYear W22462493212021 @default.
• W2246249321 countsByYear W22462493212022 @default.
• W2246249321 countsByYear W22462493212023 @default.
• W2246249321 crossrefType "journal-article" @default.
• W2246249321 hasAuthorship W2246249321A5001797354 @default.
• W2246249321 hasAuthorship W2246249321A5005474411 @default.
• W2246249321 hasAuthorship W2246249321A5010938604 @default.
• W2246249321 hasAuthorship W2246249321A5012380788 @default.
• W2246249321 hasAuthorship W2246249321A5013658911 @default.
• W2246249321 hasAuthorship W2246249321A5027037303 @default.
• W2246249321 hasAuthorship W2246249321A5040708686 @default.
• W2246249321 hasAuthorship W2246249321A5042700545 @default.
• W2246249321 hasAuthorship W2246249321A5043050636 @default.
• W2246249321 hasAuthorship W2246249321A5043093544 @default.
• W2246249321 hasAuthorship W2246249321A5048499083 @default.
• W2246249321 hasAuthorship W2246249321A5051567097 @default.
• W2246249321 hasAuthorship W2246249321A5056592494 @default.
• W2246249321 hasAuthorship W2246249321A5065804797 @default.
• W2246249321 hasAuthorship W2246249321A5068350308 @default.
• W2246249321 hasAuthorship W2246249321A5070471459 @default.
• W2246249321 hasAuthorship W2246249321A5070900971 @default.
• W2246249321 hasAuthorship W2246249321A5072977147 @default.
• W2246249321 hasAuthorship W2246249321A5090261662 @default.
• W2246249321 hasConcept C126322002 @default.
• W2246249321 hasConcept C137061746 @default.
• W2246249321 hasConcept C143998085 @default.
• W2246249321 hasConcept C147483822 @default.
• W2246249321 hasConcept C197934379 @default.
• W2246249321 hasConcept C202751555 @default.
• W2246249321 hasConcept C203014093 @default.
• W2246249321 hasConcept C22070199 @default.
• W2246249321 hasConcept C2776090121 @default.
• W2246249321 hasConcept C2778375690 @default.
• W2246249321 hasConcept C2778570526 @default.
• W2246249321 hasConcept C2779053233 @default.
• W2246249321 hasConcept C2780868878 @default.
• W2246249321 hasConcept C55493867 @default.
• W2246249321 hasConcept C71924100 @default.
• W2246249321 hasConcept C86803240 @default.
• W2246249321 hasConcept C8891405 @default.
• W2246249321 hasConceptScore W2246249321C126322002 @default.
• W2246249321 hasConceptScore W2246249321C137061746 @default.
• W2246249321 hasConceptScore W2246249321C143998085 @default.
• W2246249321 hasConceptScore W2246249321C147483822 @default.
• W2246249321 hasConceptScore W2246249321C197934379 @default.
• W2246249321 hasConceptScore W2246249321C202751555 @default.
• W2246249321 hasConceptScore W2246249321C203014093 @default.
• W2246249321 hasConceptScore W2246249321C22070199 @default.
• W2246249321 hasConceptScore W2246249321C2776090121 @default.
• W2246249321 hasConceptScore W2246249321C2778375690 @default.
• W2246249321 hasConceptScore W2246249321C2778570526 @default.
• W2246249321 hasConceptScore W2246249321C2779053233 @default.
• W2246249321 hasConceptScore W2246249321C2780868878 @default.
• W2246249321 hasConceptScore W2246249321C55493867 @default.
• W2246249321 hasConceptScore W2246249321C71924100 @default.
• W2246249321 hasConceptScore W2246249321C86803240 @default.
• W2246249321 hasConceptScore W2246249321C8891405 @default.
• W2246249321 hasIssue "15_suppl" @default.
• W2246249321 hasLocation W22462493211 @default.
• W2246249321 hasOpenAccess W2246249321 @default.

• next